Ensysce Biosciences annual r&d spending
2020
2021
2022
2023
2024
2025
Ensysce Biosciences R&D Spending Growth & History (ENSC)
Ensysce Biosciences's r&d spending was $10.4M for fiscal 2025.
View full Ensysce Biosciences company overviewEnsysce Biosciences annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.4M | $3.2M | +43.74% |
| 2024 | 2024-12-31 | $7.2M | −$368,036 | −4.85% |
| 2023 | 2023-12-31 | $7.6M | −$12.2M | −61.75% |
| 2022 | 2022-12-31 | $19.8M | $15.1M | +322.93% |
| 2021 | 2021-12-31 | $4.7M | $300,503 | +6.85% |
| 2020 | 2020-12-31 | $4.4M | — | — |
Ensysce Biosciences quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.5M | $548,322 | +28.51% |
| Q1 2026 | 2026-03-31 | $3.3M | $1.5M | +77.50% |
| Q4 2025 | 2025-12-31 | $3.6M | −$189,602 | −4.99% |
| Q3 2025 | 2025-09-30 | $3.0M | $1.3M | +74.78% |
| Q2 2025 | 2025-06-30 | $1.9M | $976,201 | +103.06% |
| Q1 2025 | 2025-03-31 | $1.9M | $1.1M | +142.07% |
| Q4 2024 | 2024-12-31 | $3.8M | $1.6M | +70.31% |
| Q3 2024 | 2024-09-30 | $1.7M | −$224,296 | −11.71% |
| Q2 2024 | 2024-06-30 | $947,229 | −$696,497 | −42.37% |
| Q1 2024 | 2024-03-31 | $778,904 | −$1.0M | −56.63% |
| Q4 2023 | 2023-12-31 | $2.2M | −$4.4M | −66.32% |
| Q3 2023 | 2023-09-30 | $1.9M | −$2.8M | −59.74% |
| Q2 2023 | 2023-06-30 | $1.6M | −$3.7M | −69.05% |
| Q1 2023 | 2023-03-31 | $1.8M | −$1.3M | −42.80% |
| Q4 2022 | 2022-12-31 | $6.6M | $4.4M | +197.52% |
| Q3 2022 | 2022-09-30 | $4.8M | $3.0M | +177.38% |
| Q2 2022 | 2022-06-30 | $5.3M | $4.8M | +1046.61% |
| Q1 2022 | 2022-03-31 | $3.1M | $2.9M | +1004.20% |
| Q4 2021 | 2021-12-31 | $2.2M | — | — |
| Q3 2021 | 2021-09-30 | $1.7M | $821,644 | +92.01% |
| Q2 2021 | 2021-06-30 | $463,219 | −$941,027 | −67.01% |
| Q1 2021 | 2021-03-31 | $284,378 | — | — |
| Q3 2020 | 2020-09-30 | $892,991 | — | — |
| Q2 2020 | 2020-06-30 | $1.4M | — | — |
Ensysce Biosciences r&d spending trends
Over the last five fiscal years, Ensysce Biosciences's r&d spending increased from $4.4M to $10.4M, a change of $6.0M. The latest reported quarter, Q2 2026, shows $2.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ensysce Biosciences source filings ↗